Personalised Medicine: Milestone In The Therapy Control Of Humanised Antibodies

Main Category: Pharma Industry / Biotech Industry
Also Included In: Cancer / Oncology
Article Date: 22 Jul 2007 - 1:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

CENiMED GmbH, BioTeZ Berlin-Buch GmbH and Invitek Gesellschaft für Biotechnik & Biodesign mbH (company for biotechnology and bio-design) announce their cooperation in the development, production and marketing of Recovery-ELISAs for therapy control of a new group of therapeutics, the so called humanised antibodies.

Humanised antibodies offer unforeseen potentialities in cancer therapy, e. g. for the treatment of mamma carcinoma. Previous therapy control methods, however, could not avoid overdoses which had caused adverse reactions with the patients. Recovery-ELISA (R-ELISA) is an innovative, patented ELISA technique for the determination of the exact efficacy concentration of the therapeutic antibodies and the therapy control. The automation of this technique will be established by a renowned platform manufacturer and then will be made available for the patients and the pharmaceutical industry.

"For the first time possibilities for a patient-specific therapy with humanised antibodies will be available" expresses Dr. Bendzko, CEO of Invtek Gesellschaft für Biotechnik & Biodesign mbH.

Dr. Pavel Strohner, CEO of BioTeZ Berlin-Buch GmbH and developer of this novel R-ELISA test, is a leading expert in the field of ELISA technology. The Berlin location is proud of this epochal development. This is yet another demonstration of the potentials and successes of a cooperation of several innovative biotechnological companies.

"This is yet another important milestone for the implementation of personalised medicine with the patients" complements Dr. Volker Muschalek, CEO of CENiMED GmbH.

About CENiMED GmbH

CENiMED GmbH - Centre for Individualised Medicine - was established in 2003 as a spin-off of the Charité Universitätsmedizin Berlin, Germany, with the intention to commercialise the results of medical fundamental research in the field of pharmacogenomics. It is a leading bio-medical company in the area of pharmacogenomic services. The company focuses on the development and marketing of services and products for the pharmaceutical industry. Herewith, CENiMED supports their clients from the early phases of drug development to post marketing studies. CENiMED is located in the Biotech Park, Berlin-Buch, Germany and possesses state-of-the-art genotyping and gene expression laboratories. Its mission is the development of early diagnostic and prognostic products on the basis of patent specific biomarkers.

About BioTeZ GmbH

Biotez Berlin-Buch GmbH, is a biotechnologically oriented company, was established 10 years ago and is situated on the Biotech campus Berlin-Buch since 1992

BioTeZ focuses on the following areas: Bio-diagnostics and food analytics, scientific services for genetic research and biotechnology and Custom oligonucleotide synthesis.

Additionally, the companies' experts have special experience and know-how in the conjugation and labelling of bio molecules (with HRP, FITC a. o.), development of monoclonal and polyclonal antibodies, ELISA development, Streptavidin coating (high biotin binding capacity, high chemo- and thermo stability) and immuno-affinity columns and chromatography.

About Invitek Gesellschaft für Biotechnik & Biodesign mbH

Invitek GmbH is a world-wide operating company that offers innovative products and technical support for the Life Science and diagnostics industries.

Founded in 1992, the company is known internationally for its outstanding and powerful technology platforms and also offers a wide range of innovative products for the nucleic acid purification, molecular diagnostics, the pharmaceutical industry and bio medical research. Within the modular product concept "I-tek solution", Invitek combines its technological developments in complete solutions for molecular diagnostics. An example is the successful introduction of an early warning system for colon carcinoma.

The company is certified according to DIN EN ISO 9001:2000 and EN ISO 13485:2003 and manufactures according to EC Directive 98/79/EEC (IVD-MD).

http://www.invitek.de
http://www.biotez.de
http://www.cenimed.com